Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00116701 | Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis | PHASE3 | COMPLETED | 200 | — | — | May 1, 2005 | - | May 5, 2008 | - | — |
| NCT00124098 | An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD) | PHASE3 | COMPLETED | - | — | — | - | - | Jun 16, 2008 | - | — |
| Name | Type | Description |
|---|---|---|
| Aranesp® | DRUG | - |
| Aranesp® (darbepoetin alfa) | DRUG | - |
Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater ...